Young at heart

Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells

Aoife Gowran, Marco Rasponi, Roberta Visone, Patrizia Nigro, Gianluca L. Perrucci, Stefano Righetti, Marco Zanobini, Giulio Pompilio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based models of nonischaemic cardiomyopathy.

Original languageEnglish
Article number4287158
JournalStem Cells International
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Induced Pluripotent Stem Cells
Cardiomyopathies
Preclinical Drug Evaluations
Stem Cells
Fibroblasts
Research Personnel
Technology

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Young at heart : Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells. / Gowran, Aoife; Rasponi, Marco; Visone, Roberta; Nigro, Patrizia; Perrucci, Gianluca L.; Righetti, Stefano; Zanobini, Marco; Pompilio, Giulio.

In: Stem Cells International, Vol. 2016, 4287158, 2016.

Research output: Contribution to journalArticle

Gowran, Aoife ; Rasponi, Marco ; Visone, Roberta ; Nigro, Patrizia ; Perrucci, Gianluca L. ; Righetti, Stefano ; Zanobini, Marco ; Pompilio, Giulio. / Young at heart : Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells. In: Stem Cells International. 2016 ; Vol. 2016.
@article{5d0be0cbcd854ad19c896ece2e0eb6d0,
title = "Young at heart: Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells",
abstract = "A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based models of nonischaemic cardiomyopathy.",
author = "Aoife Gowran and Marco Rasponi and Roberta Visone and Patrizia Nigro and Perrucci, {Gianluca L.} and Stefano Righetti and Marco Zanobini and Giulio Pompilio",
year = "2016",
doi = "10.1155/2016/4287158",
language = "English",
volume = "2016",
journal = "Stem Cells International",
issn = "1687-966X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Young at heart

T2 - Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells

AU - Gowran, Aoife

AU - Rasponi, Marco

AU - Visone, Roberta

AU - Nigro, Patrizia

AU - Perrucci, Gianluca L.

AU - Righetti, Stefano

AU - Zanobini, Marco

AU - Pompilio, Giulio

PY - 2016

Y1 - 2016

N2 - A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based models of nonischaemic cardiomyopathy.

AB - A mere 9 years have passed since the revolutionary report describing the derivation of induced pluripotent stem cells from human fibroblasts and the first in-patient translational use of cells obtained from these stem cells has already been achieved. From the perspectives of clinicians and researchers alike, the promise of induced pluripotent stem cells is alluring if somewhat beguiling. It is now evident that this technology is nascent and many areas for refinement have been identified and need to be considered before induced pluripotent stem cells can be routinely used to stratify, treat and cure patients, and to faithfully model diseases for drug screening purposes. This review specifically addresses the pioneering approaches to improve induced pluripotent stem cell based models of nonischaemic cardiomyopathy.

UR - http://www.scopus.com/inward/record.url?scp=84964829795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964829795&partnerID=8YFLogxK

U2 - 10.1155/2016/4287158

DO - 10.1155/2016/4287158

M3 - Article

VL - 2016

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-966X

M1 - 4287158

ER -